Introduction
The selective estrogen receptor modulator (SERM) tamoxifen (TAM) is the most widely prescribed endocrine therapy for the treatment and prevention of breast cancer in premenopausal women, while aromatase inhibitors are the drug of choice for post-menopausal women. De novo or acquired resistance to these endocrine therapies limits their clinical effectiveness leading to disease progression. As such, there is a clinical need for therapeutic alternatives for women who no longer respond to conventional endocrine therapies.
Protein kinase C alpha (PKCα) belongs to a family of serine/threonine protein kinases (1, 2) . PKCα expression in breast cancer is associated with TAM-resistance, poor patient survival and breast cancer aggressiveness (3) (4) (5) .
To further substantiate these clinical observations we reported that ectopic overexpression of PKCα in the T47D:A18 breast cancer cell line resulted in a hormone-independent, TAM-resistant phenotype (6) . Interestingly, these TAMresistant T47D:A18/PKCα tumors are growth inhibited by 17β-estradiol (E2) in vivo (7). Yao and colleagues describe an MCF-7 tumor model in which long-term exposure (5 years) to TAM led to an E2-inhibited phenotype (8) and elevated PKCα expression (7). Together these studies provide important therapeutic implications, suggesting that PKCα expression may predict both resistance to conventional endocrine therapies as well as a predicted response to E2 or estrogen-like compounds.
Before the introduction of TAM, breast cancer patients were treated with high-dose E2 or diethystilbesterol (DES). Although, similar response rates were 4 observed (9, 10), TAM treatment became the mainstay due to a lower incidence of side effects such as nausea, emesis and edema. Since treatment with E2, DES and TAM are now all associated with side effects including increased risk of thromboembolic disorders and unwanted agonist-driven uterine growth, we sought an alternative treatment strategy that would have therapeutic efficacy in the TAM-resistant setting. We have previously reported that TAM-resistant T47D:A18/PKCα tumors regress upon treatment with both E2 and the benzothiophene SERM raloxifene (RAL), although the effects of RAL did not persist after treatment withdrawal (11). RAL has a favorable antiestrogenic profile in the uterus and has proven safety over 15 years of clinical use in postmenopausal osteoporosis and breast cancer chemoprevention.
In this study, we tested the in vivo effects of two novel benzothiophene SEMs induced regression of TAM-resistant, hormone-independent T47D:A18/PKCα and T47D:A18-TAM1 xenograft tumors in vivo, but remarkably, neither compound was able to support the growth of hormone-dependent, TAMsensitive T47D:A18/neo tumors. Of particular importance is that neither SEM caused any significant increase in the uterine weights of treated mice. These data suggest that patients exhibiting endocrine resistance may respond to benzothiophene SEMs using PKC as a predictive biomarker. 
Cell culture conditions
Stable transfectant cell lines T47D:A18/neo and T47D:A18/PKCα were produced and maintained as previously described (6) in RPMI1640 (phenol red) supplemented with 10% fetal bovine serum (FBS) containing G418 (500 μg/ml). T47D cells were initially obtained from ATCC in 1996 and stored during early passage. MCF-7 cells were originally obtained from the Michigan Cancer Foundation (Detroit, MI, USA) in 1992 and stored during early passage. MCF-7:5C cells were maintained E2-depleted media as previously described (12).
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The T47D:A18-TAM1 cell line was created by maintaining T47D:A18 breast cancer cells long-term (12 months) in 1uM of 4-hydroxytamoxifen (4-OHT) in E2-depleted media. Single cell clones were derived using the limiting dilution method. All TAM-resistant cell lines retain estrogen receptor alpha (ERα) expression at varying levels compared to their TAM-sensitive counterparts (Supplemental Figure 1) . Prior to treatment cell lines were cultured in E2-depleted media for 3 days. Cell lines were routinely tested for mycoplasma contamination (MycoAlert TM Mycoplasma Detection Kit, Lonza Ltd., Rockland, ME, USA). All cell lines were authenticated in April 2014 using short tandem repeat (STR) and ATCC analysis (Promega Corporation Core Genomics Facility, UIC).
Synthesis and oral bioavailability of BTC
The synthesis of BTC and TTC-352 has been described (13). Dansyl derivatization of BTC was employed to increase limits of detection and quantitation for LC-MS/MS analysis of plasma samples (Supplemental Figures 2   and 3 ). Working solutions of BTC and internal standard (3-Br-BTC) were prepared by serial dilution of 1 mg/mL acetonitrile stocks. Calibration standards were prepared by spiking BTC or 3-Br-BTC (20ng/mL) into blank mouse plasma to give a final concentration range of 5-100 ng/mL (Supplemental Figure 4 ). After addition of cold acetonitrile, samples were kept at 4 °C for 2 h, centrifuged at 10,000 rpm for 15 min, and supernatants were concentrated under N 2 stream.
Resulting residues were reconstituted in 0.1 mL of 100 mM sodium bicarbonate 7 buffer (pH=10.5) and derivatized by addition of 0.1 mL dansyl chloride (2 mg/mL in acetone) followed by incubation at 60°C for 5 min. 
Proliferation assay
Following 3 days of growth in E2-depleted media, 2 × 10 5 cells were seeded into T25 tissue culture flasks. The following day (day 1) treatment medium was added. Cells were counted on Day 9 and medium was changed every 3 days.
Western Blot
Whole cell extracts of cultured cells were prepared in lysis buffer (200 mM Tris, 1% Triton X-100, 5mM EDTA) with protease and phosphatase inhibitor cocktails (1:50, both from Sigma-Aldrich) after scraping from the culture plates.
Protein concentration was measured using the Bradford method (Bio-Rad,
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Hercules, 26 CA). Proteins were separated under denaturing conditions, blotted onto nitrocellulose membrane (Bio-Rad) using a wet transfer system (Bio-Rad).
Images of blots were acquired on a Bio-Rad ChemiDoc System following incubation with SuperSignal West Dura luminol solution (Thermo Fisher Scientific). Protein bands were quantified using densitometry measured in Adobe Photoshop CS4 (San Jose, CA) and normalized to β-actin. 
Transient transfection and luciferase assays

Animal experiments
T47D:A18/PKCα, T47D:A18/neo and T47D:A18-TAM1 tumors were established as previously described (7). E2 was administered via silastic capsules (1.0 cm) implanted subcutaneously between the scapulae, producing a mean serum E2 level of 379.5 pg/mL (11, 15). BTC and TTC-352 were administered p.o. at a dose of 1.5 mg/animal daily for 2 weeks as previously described for other SERMs (7). RAL was administered p.o. at a dose 1.5 mg/animal daily for 2 weeks. Tumor cross-sectional area was determined weekly using Vernier calipers and calculated using the formula: length / 2 × width / 2 × π.
Mean tumor area was plotted against time in weeks to monitor tumor growth.
The mice were sacrificed by CO 2 inhalation and cervical dislocation, and tumors 11 and uteri were excised, cleaned of connective tissue, and immediately weighed.
The Animal Care and Use Committee of the University of Illinois at Chicago approved all of the procedures involving animals.
Tumor immunofluorescence and confocal microscopy
Tumor sections (4 μm) were cut from paraffin blocks and prepared for IF staining by deparaffinization and rehydration as previously described (11).
Briefly, antigen retrieval was performed by incubating slides in Tris-EDTA (pH = 9.0) buffer. Slides were blocked with antibody diluent (DAKO, Carpinteria, CA USA) followed by primary antibodies at 1:100 in antibody diluent for 1 h, then incubated with secondary antibodies at 1:100 in antibody diluent for 45 min followed by DAPI (4', 6-diamidino-2-phenylindole [1 μg/mL], DAKO, Carpinteria, CA USA). Confocal analysis was performed with a Zeiss LSM 510 microscope (Carl Zeiss, Incorporated, North America, Thornwood, NY USA).
Statistical analyses
Statistics were run using GraphPad Prism Version 5.0. Statistical analyses used were one-way ANOVA followed by Tukey's post-test or Student's t-test where appropriate. 
Bioavailability of BTC and benzothiophene SERMs
In humans, the absolute bioavailability of orally administered RAL is reported as 2%, with oral clearance of 44 l/kg/h (18, 19 
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agonist actions in bone tissues, however, it also has poor bioavailability (20) .
Arzoxifene was designed as a DMA prodrug to overcome the problems associated with low bioavailability (21) (22) (23) (24) . As part of a comparative study of biological activity of DMA, arzoxifene and F-DMA in juvenile female rats, metabolism was assessed by quantification of remaining drug in plasma after 3 days of drug administration: DMA was not observed above detection limits, whereas arzoxifene and F-DMA were easily quantifiable (25) (26) (27) . BTC is the benzothiophene core of DMA and RAL, whereas TTC-352 bears structural similarity with F-DMA. Consequently, we were concerned that the bioavailability of BTC would be too low for study in vivo (24, 25, 27, 28) . Therefore, plasma levels of BTC were measured after oral administration to ovariectomized athymic nude mice. Since BTC ionizes poorly by electrospray ionization ESI-MS, a chemical derivatization method was developed using tandem mass spectroscopic MRM analysis.
Drug was detected in plasma at a peak concentration of 40 ng/mL at 30 min, which fell to 10 ng/mL after 6 h (Supplemental Figure 6 ). Given the observation of BTC well above detection limits in mouse plasma, it was decided to compare the effects of BTC and TTC-352 with RAL and E2 in the T47D:A18/PKCα xenograft model using oral delivery.
SEMs cause regression of hormone-independent, TAM-resistant xenografts
We recently reported that RAL treatment results in significant regression At that time, the mice were randomized to four treatment groups; continued no treatment (control arm, 9 mice), E2 capsule (9 mice), oral RAL 1.5 mg/day (9 mice), oral BTC 1.5 mg/day (9 mice), or oral TTC-352 1.5 mg/day (4 mice). show similar efficacy to E2 causing significant tumor regression in two TAMresistant breast cancer xenografts.
SEMs do not support growth of hormone-dependent xenografts
The ER-positive, hormone-dependent T47D:A18/neo breast cancer cell Therefore SEMs are capable of causing regression of endocrine-resistant breast cancer xenografts, and importantly they are unable to support the growth of hormone-dependent xenografts in vivo. This result is significant as it suggests that SEMs will not stimulate the growth of any endocrine-sensitive breast cancer cells that may be present in heterogeneous tumors.
SEMs are without uterotrophic actions in athymic mice
E2 has a proliferative effect on the endometrium resulting in an increase in uterine weight. TAM has an estrogenic effect on endometrial growth, which leads to an increased risk of developing endometrial cancer (29) . In ovariectomized rats at a minimally effective dose, RAL did not increase uterine weight in contrast to E2 and TAM, and at doses up to 10 mg/kg/day did not increase luminal epithelial cell thickness (30) (31) (32) (33) . Mindful of the in vitro estrogen agonist actions of BTC and TTC-352 described above, we sought to compare the effects on uterine weight of BTC, TTC-352, RAL, TAM, and E2. Following 7 weeks of treatment the uteri from the ovariectomized mice used in the T47D:A18/neo xenograft study ( Figure 6A ) were excised and weighed.
Interestingly, BTC and TTC-352 caused no significant increase in the uterine weights of the treated mice ( Figure 6C ). The SEM-treated mice were indistinguishable from those that were treated with RAL, which is known to be without uterotrophic actions. In contrast, and as expected, TAM and E2 caused significant increases in uterine weight. 
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women who no longer respond to conventional, endocrine therapy. The combination of the aromatase inhibitor exemestane with the mTOR inhibitor everolimus improved progression-free survival for endocrine-resistant breast cancer patients, however an increased toxicity profile was observed in patients who took the combined treatment (37) . There is a clinical need to provide endocrine-therapy resistant patients with effective and safe alternatives. Our findings and those of others suggest that PKCα expression is a predictive marker of disease outcome for patients on endocrine therapy (3) (4) (5) . Further PKCα expression may predict a positive response to E2 or an E2-like compound (7).
E2 has clinical efficacy (9, 34, 38, 39), but due to unfavorable side effects it is no longer used for treatment.
Recently, the use of E2 or an E2-like compound has re-emerged as a possible treatment strategy for patients exhibiting endocrine therapy resistant breast cancers (40, 41) . Clinical trials have demonstrated the efficacy of E2 in this setting (38, 39) . In fact, a long-term follow up study indicated a survival advantage for patients treated with the synthetic estrogen DES compared to 
